Jazz Pharmaceuticals plc Earnings Recaps
Jazz’s shares rose 7.1% after the company reported record third-quarter revenue of $1.24 billion, up 10% year over year, and raised its 2026 revenue guidance. The early Ziihera launch and 35% oncology revenue growth were notable positives.
Key takeaways
- Xywav sales increased 12% to $483 million; Jazz added approximately 425 net patients during the quarter across narcolepsy and idiopathic hypersomnia.
- Oncology revenue grew 35% year over year, with management citing Modeyso and first-line maintenance Zepzelca launches as drivers.
- Jazz completed its Actio Biosciences acquisition, adding the clinical-stage epilepsy candidate ABS-1230; initial patient data are expected at a medical meeting this quarter.
- Management said evolving competition from orexin 2 receptor agonists could lengthen the time some new patients take to initiate Xywav.
Jazz Pharmaceuticals shares rose 3.5% following a quarter driven by broad-based portfolio growth with multiple product lines exceeding expectations, particularly Xywav and Epidiolex. The market rewarded strong commercial execution and confidence in upcoming oncology launches.
Key takeaways
- Total revenue reached $1.2 billion, up 16% year-over-year, reflecting sustained demand and effective commercialization across key products.
- Xywav net product sales grew 13% to $471 million, supported by continued new patient additions (+525 in the quarter) and an expanding active patient base now exceeding 17,000.
- Epidiolex sales increased 16% to $292 million, benefiting from ongoing educational efforts and the introduction of a novel capsule formulation targeting improved adherence in adult patients.
- Oncology portfolio showing early momentum as Ziihera generated $15 million in second-line BTC sales, capturing over 50% U.S. market share in the segment.
- Management highlighted readiness to launch zanidatamab in first-line HER2-positive metastatic GEA, leveraging existing commercial infrastructure to drive near-term growth.
Jazz Pharmaceuticals shares rose 6.9% post-earnings, reflecting investor approval of better-than-expected revenue growth and encouraging commercial momentum across key product lines.
Key takeaways
- Total revenues reached a record $1.1 billion in Q1 2026, marking over 19% year-over-year growth.
- Xywav sales grew 18% to $408 million with about 16,600 active patients and 425 net patient additions.
- Epidiolex sales increased 15% to $250 million, driven by 16% volume growth and expanded adult patient reach.
- Early commercial uptake of Ziihera yielded $13 million in net sales, with preparations underway for a potential GEA launch following FDA priority review.
- Generated over $400 million in cash flow and non-GAAP adjusted EPS of $6.34, supporting ongoing R&D and business development investments.
Jazz Pharmaceuticals achieved record revenues of over $1.1 billion in Q3 2025, fueled by strong sales across its product portfolio and two significant FDA approvals, paving the way for continued growth and strategic advancements.
Key takeaways
- Secured FDA approvals for Modeyso and Zepzelca, expanding treatment options for severe conditions.
- Strong commercial performance driven by Xywav's 11% year-over-year growth, contributing $431 million in net sales.
- Narrowed 2025 revenue guidance to $4.175 billion - $4.275 billion, reflecting confidence in future performance.
- Completed settlements in Xyrem antitrust litigation, allowing focus on strategic execution and shareholder value.
- Strengthened the pipeline with the Saniona licensing agreement for a promising epilepsy candidate, SAN2355.